Compare Cassava Sciences Inc (FLNA) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Harmony Gold Mining Co. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B). The key difference: Harmony Gold Mining Co. is far larger — about 254.3× Cassava Sciences Inc's market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Harmony Gold Mining Co. for 45 Days on average.
| FLNA | HMY | |
|---|---|---|
Market Cap | $39.40M | $10.02B |
Volume | 759,018 | 3,643,683 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $26.04 |
52-Week Low | $0.68 | $13.32 |
Typical Hold Time | 37 Days | 45 Days |
Enterprise Value | -$43.28M | $10.07B |
Dividend Yield | — | 4.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
HMY trades at $16.83, up 2.03% today, amid a bearish technical signal from moving averages. The company reported record fiscal 2026 revenue of $99.2B and net income of $29.3B, with a strong net margin of 29.57%. Recent news highlights its strategic shift toward copper production, with the CEO noting the real payoff is expected after 2030. Cash flow from operations surged to $22.65B in 2025, though 2026 projections show a net cash outflow due to heavy investing.
The outlook is mixed: strong fundamentals and undervalued ratios (P/E of 6.02) support upside, but technical weakness and two recent EPS misses pose near-term risks. Analyst consensus is cautious with 70% hold ratings. Key opportunities include copper diversification; risks involve execution on investments and gold price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
